Di Yi Cai Jing·2025-09-02 07:20Core Viewpoint - BeiGene's market capitalization has surpassed 500 billion yuan, making it the highest-valued pharmaceutical stock in A-shares, marking a significant milestone for the company [1] Group 1: Market Performance - On September 2, BeiGene's A-share price surged by 9.84%, reaching a total market value of 507.4 billion yuan [1] - As of 1:39 PM on the same day, the company's market value was still at 502.3 billion yuan [1] - This marks the first time BeiGene's A-share market value has exceeded 500 billion yuan [1] Group 2: Industry Context - Prior to BeiGene, other pharmaceutical stocks in the A-share market, such as Hengrui Medicine, had also reached the 500 billion yuan market cap milestone [1] - The pharmaceutical sector experienced a cooling period after mid-2021, but has seen a revaluation of stock values since the first half of 2025, driven by active external licensing transactions [1] Group 3: Financial Performance - Since the beginning of 2025, BeiGene's A-share stock price has doubled [1] - In the first half of 2025, the company reported revenue of 17.518 billion yuan, a year-on-year increase of 46% [1] - The net profit attributable to the parent company was 450 million yuan, marking a turnaround from losses to profitability [1] - This is the first time in BeiGene's history that it achieved profitability through product sales rather than external licensing [1]